These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7295341)

  • 21. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.
    Bull JM; Strebel FR; Sunderland BA; Bulger RE; Edwards M; Siddik ZH; Newman RA
    Cancer Res; 1988 Apr; 48(8):2239-44. PubMed ID: 3349489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of O-(beta-hydroxyethyl)-rutoside on the glucose metabolism of cultured human varicose saphenous veins.
    Matagne D; Gilles R
    Arch Int Physiol Biochim; 1977 Feb; 85(1):133-8. PubMed ID: 68718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double blind trial of oral O. B-hydroxyethyl rutosides for stasis leg ulcers.
    Mann RJ
    Br J Clin Pract; 1981 Feb; 35(2):79-81. PubMed ID: 7020736
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of Troxerutin on the hemorheological parameters of patients with moderate arterial hypertension.
    Gueguen-Duchesne M; Durand F; Le Goff MC; Genetet B
    Prog Clin Biol Res; 1988; 280():401-6. PubMed ID: 3174703
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of O-(beta-hydroxyethyl)-rutoside on wound healing in the rat.
    Wilhelmi G
    Pharmacology; 1979; 19(2):82-5. PubMed ID: 531085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, cross-over trial of O-(beta-hydroxyethyl)-rutosides (benzo-pyrones) in the treatment of lymphoedema of the arms and legs.
    Piller NB; Morgan RG; Casley-Smith JR
    Br J Plast Surg; 1988 Jan; 41(1):20-7. PubMed ID: 3278764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative determination of O-(beta-hydroxyethyl)-rutosides in serum by high-performance liquid chromatography.
    Kuhnz W; Zech K; Lupp R; Jung G; Voelter W; Matzkies F
    J Chromatogr; 1983 Feb; 272(2):333-40. PubMed ID: 6833430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of acute symptoms of hemorrhoid disease with high-dose oral O-(beta-hydroxyethyl)-rutosides].
    Annoni F; Boccasanta P; Chiurazzi D; Mozzi E; Oberhauser V
    Minerva Med; 1986 Sep; 77(37):1663-8. PubMed ID: 3531924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pharmacological and clinical properties of the venoactive agent: Venoruton (Paroven). Studies presented at the 1st Mediterranean Congress of Angiology. Corfu, Greece, May 29 to June 3, 1988. Abstracts.
    Int Angiol; 1988; 7(4 Suppl):1-16. PubMed ID: 3249081
    [No Abstract]   [Full Text] [Related]  

  • 30. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds.
    Pincemail J; Deby C; Thirion A; de Bruyn-Dister M; Goutier R
    Experientia; 1988 May; 44(5):450-3. PubMed ID: 2836234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Studies in animal experiments on determination of blood and organ levels of o-(beta-hydroxyethyl)-rutosides (HR) after i.p. administration (author's transl)].
    Reinartz G; Wurst F
    Arzneimittelforschung; 1980; 30(4):657-9. PubMed ID: 7190409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of o-(beta-hydroxyethyl)-rutoside in lymphangiography.
    Broks PD
    AJR Am J Roentgenol; 1977 Feb; 128(2):263-5. PubMed ID: 401613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of benzopyrones on pancreatic secretion in anaesthetized dogs with short-term ischaemia.
    Nozicková M; Bartos V; Hachowá L
    Mater Med Pol; 1981; 13(1):23-5. PubMed ID: 7321583
    [No Abstract]   [Full Text] [Related]  

  • 34. The disposition and metabolism of 3',4',7-tri-O-(beta-hydroxyethyl)rutoside and 7-mono-O-(beta-hydroxyethyl)rutoside in the mouse.
    Hackett AM; Griffiths LA
    Xenobiotica; 1977 Oct; 7(10):641-51. PubMed ID: 910465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flavonoid-induced delay in the small intestinal transit: possible mechanism of action.
    Viswanathan S; Thirugnana Sambantham P; Bapna JS; Kameswaran L
    Arch Int Pharmacodyn Ther; 1984 Jul; 270(1):151-7. PubMed ID: 6497500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of O-(beta-hydroxyethyl)-rutoside (HR) on macromolecular leakage, thrombosis and haemostasis in experimental animals.
    Bergqvist D; Svensjö E; Arfors KE
    Ups J Med Sci; 1978; 83(2):123-7. PubMed ID: 664118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rutosides and radiation induced regression of experimental tumours.
    Fritz-Niggli H; Rao KR
    Arzneimittelforschung; 1977; 27(5):1057-64. PubMed ID: 577871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrophotofluorometric analysis of 3',4',7-tris[O-(beta-hydroxyethyl)]rutoside in urine.
    Tan HS; Mowery PJ; Ritschel WA; Neu C
    J Pharm Sci; 1978 Aug; 67(8):1142-4. PubMed ID: 671254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hydroxyethyl rutosides upon the permeability of single capillaries in the frog mesentery.
    Blumberg S; Clough G; Michel C
    Br J Pharmacol; 1989 Apr; 96(4):913-9. PubMed ID: 2787181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of venoruton on hypoxic stress-induced neurotoxicity in mice and oxygen free radical generation by human neutrophils.
    Shukla VK; Sethi AK; Garg SK; Ganguly NK; Kulkarni SK
    Arch Int Pharmacodyn Ther; 1989; 299():127-33. PubMed ID: 2774763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.